Ozempic (semaglutide) typically lowers A1C by 1.2% to 1.8%, depending on the dose and whether it’s used alone or with other medications. For someone starting with an A1C of 8.5%, that could mean dropping into the 7% range or lower. In terms of daily blood sugar readings, the 1 mg dose reduces fasting glucose by about 29 mg/dL and post-meal spikes by roughly 74 mg/dL compared to no treatment.
A1C Reductions by Dose
Ozempic comes in three doses: 0.5 mg, 1 mg, and 2 mg, each injected once weekly. The blood sugar lowering effect scales with the dose, though not dramatically. Across multiple large clinical trials, the results were consistent:
- 0.5 mg dose: A1C dropped by 1.2% to 1.5% from baseline
- 1 mg dose: A1C dropped by 1.5% to 1.8% from baseline
- 2 mg dose: A1C dropped by about 2.1% in patients who started with higher baseline levels (average A1C of 8.9%)
The higher your starting A1C, the larger the absolute drop tends to be. In the trial testing the 2 mg dose, participants began with an average A1C near 9%, which partly explains the bigger reduction. Someone starting at 7.5% won’t see the same size drop simply because there’s less room to fall.
What Happens to Daily Blood Sugar Readings
A1C is a three-month average, so it doesn’t tell you what’s happening day to day. The FDA label for Ozempic provides those numbers for the 1 mg dose. Compared to placebo, fasting blood sugar fell by 29 mg/dL (a 22% reduction), and the average 24-hour glucose level dropped by 30 mg/dL.
The most dramatic effect was on post-meal glucose. Two hours after eating, blood sugar was 74 mg/dL lower than it would have been without treatment, a 36% reduction. This is significant because post-meal spikes are one of the hardest parts of type 2 diabetes to control, and they contribute heavily to A1C over time. If your glucose typically shoots to 220 mg/dL after a meal, Ozempic could bring that closer to 150 mg/dL.
How Ozempic Lowers Blood Sugar
Ozempic mimics a natural gut hormone called GLP-1 that your body releases after eating. This hormone does several things at once. It signals your pancreas to release more insulin, but only when blood sugar is actually elevated. This “glucose-dependent” mechanism is important because it means the drug doesn’t force insulin release when your blood sugar is already normal, which reduces the risk of dangerous lows.
At the same time, Ozempic suppresses glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. By dialing down glucagon, less glucose enters your blood between meals and overnight. The drug also slows stomach emptying, which means carbohydrates from food are absorbed more gradually, blunting those post-meal spikes. Together, these effects work on blood sugar from multiple angles.
How Quickly It Works
Blood sugar levels start declining within the first week of treatment, but the early effects are modest. Ozempic requires a gradual dose increase: you start at 0.25 mg for four weeks (which is purely a tolerability dose, not a therapeutic one), then move to 0.5 mg, and potentially up from there.
The full effect on A1C takes about 12 weeks of steady dosing at your maintenance dose. Since A1C reflects a rolling three-month average of blood sugar, this timeline makes sense. Your daily glucose readings will improve well before your A1C catches up. Most people see their most meaningful A1C result at the 12 to 16 week mark after reaching their target dose.
How It Compares to Metformin
Metformin, the most commonly prescribed first-line diabetes medication, lowers A1C by about 1.4% over a similar timeframe. The 0.5 mg Ozempic dose performs comparably, while the 1 mg and 2 mg doses pull ahead. No head-to-head trial has directly compared the two drugs, so these numbers come from separate studies with different patient populations. In practice, many people take both together, since they lower blood sugar through different mechanisms and their effects can stack.
Compared to long-acting insulin (Lantus), Ozempic produced similar or better A1C reductions in clinical trials. In one study, the 1 mg dose lowered A1C by 1.6% versus 1.1% with insulin, with the added benefit of weight loss rather than weight gain.
Risk of Blood Sugar Going Too Low
Because Ozempic only boosts insulin when blood sugar is elevated, the risk of hypoglycemia is low when it’s used alone or with metformin. Across clinical trials, severe hypoglycemia occurred in 1.5% or fewer of patients on Ozempic monotherapy.
The risk increases when Ozempic is combined with insulin or sulfonylureas (older diabetes pills that force insulin release regardless of blood sugar levels). In one trial of patients taking metformin with or without a sulfonylurea, confirmed hypoglycemia occurred in 4% to 6% of those on Ozempic, compared to 11% on insulin. If you’re adding Ozempic to an existing regimen that includes insulin or a sulfonylurea, your doctor will likely reduce those doses to prevent lows.
Factors That Affect Your Results
The clinical trial averages are useful benchmarks, but individual results vary. Several factors influence how much your blood sugar drops on Ozempic. Your starting A1C matters most: someone at 9.5% has more room to improve than someone at 7.8%. How long you’ve had diabetes also plays a role, since the drug relies on functioning insulin-producing cells in the pancreas. People with very long-standing type 2 diabetes may have lost enough of those cells that the response is smaller.
Diet and exercise amplify the effect. Weight loss itself improves insulin sensitivity, and Ozempic produces meaningful weight loss in most people (typically 8 to 14 pounds at the 1 mg dose). The slower stomach emptying also naturally reduces portion sizes, which cuts carbohydrate intake and further helps glucose control. Consistency with the weekly injection matters too. Missing doses or taking them irregularly prevents the drug from reaching steady levels in your system, which delays the full A1C benefit.